Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

Base Information Edit
  • Chemical Name:5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole
  • CAS No.:1030377-33-3
  • Molecular Formula:C23H23ClN6O2
  • Molecular Weight:450.928
  • Hs Code.:
  • Mol file:1030377-33-3.mol
5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

Synonyms:MK-4305

 This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Chemical Property of 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole Edit
Chemical Property:
  • Melting Point:153℃ 
  • Boiling Point:669.803 °C at 760 mmHg 
  • PKA:1.47±0.40(Predicted) 
  • Flash Point:358.884 °C 
  • PSA:80.29000 
  • Density:1.419 g/cm3 
  • LogP:4.11420 
  • Storage Temp.:Room Temperature 
  • Solubility.:Acetonitrile (Slightly), Chloroform (Slightly), DMSO (Slightly, Heated), Methano 
Purity/Quality:
Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:

SDS file from LookChem

Useful:
  • description Suvorexant (Belsomra? ) is a novel sedative hypnotic drug that is prescribed to promote sleep in patients with insomnia. It is the first of a new class of drugs classified as dual orexin receptor antagonists (DORAs) and is currently approved for the treatment of insomnia in the United States and Japan. It is a CNS depressant and blocks the binding of wake-promoting neuropeptides orexin A and orexin B to the two orexin receptors (OX1R and OX2R) thus, altering the signaling (action) of orexin in the brain and suppressing the sleep-wake drive. Suvorexant is a central nervous system (CNS) depressant and can impair daytime wakefulness even when used as prescribed. Prescribers should monitor for somnolence and CNS depressant effects, but impairment can occur in the absence of symptoms, and may not be reliably detected by ordinary clinical exam. CNS depressant effects may persist in some patients for up to several days after discontinuing Suvorexant. Belsomra (Suvorexant) can impair driving skills and may increase the risk of falling asleep while driving. Discontinue or decrease the dose in patients who drive if daytime somnolence develops. Caution patients taking Belsomra 20 mg against next-day driving and other activities requiring full mental alertness. Caution patients taking lower doses of Belsomra as well, because there is individual variation in sensitivity to Belsomra.
  • Description Suvorexant, a dual orexin receptor antagonist marketed under the trade name Belsomra?, discovered and developed by Merck for the treatment of insomnia, was approved by the US FDA in August 2014 and became available in Japan in November of the same year. The drug’s mechanism of action operates through the competitive blockade of wake-promoting neuropeptides orexin A and orexin B toward receptors orexin receptor type 1 and orexin receptor type 2, which are believed to modulate sleep-wake cycles. Suvorexant (Item No. 22911) is an analytical reference standard categorized as a diazepane sedative. Formulations containing suvorexant show abuse potential similar to zolpidem in recreational polydrug users with a history of sedative and psychedelic drug use. Suvorexant is regulated as a Schedule IV compound in the United States. This product is intended for use in analytical forensic applications. This product is also available as a general research tool . Suvorexant is a dual orexin receptor (OXR) antagonist that blocks both OX1R and OX2R (Kis = 1.2 and 0.60 nM, respectively). It reduces locomotor activity and promotes sleep by inhibiting the binding of orexin A and B. In rats, suvorexant decreases self-administration of, and conditioned place preference for, cocaine ( | 16186 | ISO60176). It also decreases dopamine levels in the rat ventral striatum following a cocaine-induced increase. Formulations containing suvorexant are used in the treatment of insomnia. This compound is also available as an analytical reference standard .
  • Uses Suvorexant (MK-4305) is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.
Technology Process of 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

There total 73 articles about 5-Chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
C13H16ClN3O*C18H14O8; With sodium hydroxide; In dichloromethane; water; at 20 ℃; for 1h;
2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoic acid; With oxalyl dichloride; In dichloromethane; N,N-dimethyl-formamide; at 0 - 10 ℃; for 1h;
5-chloro-2-[(5R)-hexahydro-5-methyl-1H-1,4-diazepin-1-yl]benzoxazole; With triethylamine; In dichloromethane; N,N-dimethyl-formamide; at 0 - 15 ℃; for 1h; optical yield given as %ee;
DOI:10.1021/op1002853
Guidance literature:
5-methyl-2-(1H-1,2,3-triazol-2-yl)benzoic acid; With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0 - 10 ℃; for 1h;
5-chloro-2-[(5R)-hexahydro-5-methyl-1H-1,4-diazepin-1-yl]benzoxazole; With triethylamine; In dichloromethane; at -10 - -5 ℃; for 1h;
Guidance literature:
With 4-methyl-morpholine; 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 20 ℃; for 3h;
DOI:10.1016/j.tetlet.2021.153014